

1 Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors

2 Maurice Steenhuis¹, Gerard van Mierlo¹, Ninotska I.L. Derksen¹, Pleuni Ooijevaar-de Heer¹, Simone
3 Kruithof¹, Floris L. Loeff¹, Lea C. Berkhout¹, Federica Linty², Chantal Reusken⁵, Johan Reimerink⁵, Boris
4 Hogema⁹, Hans Zaaijer⁴, Leo van de Watering⁷, Francis Swaneveld³, Marit J. van Gils⁶, Berend Jan Bosch⁸,
5 Marieke van Ham¹, Anja ten Brinke¹, Gestur Vidarsson², Ellen C. van der Schoot², Theo Rispens^{1, *}

8 **Running title**

9 Dynamics of SARS-CoV-2 antibodies after recovery

10

11

12 **Affiliations**

13 ¹Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and Landsteiner
14 Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

15 ²Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory
16 Academic Medical Centre, 1066 CX Amsterdam, the Netherlands.

17 ³Department of Transfusion Medicine, Sanquin Blood Bank, 1066 CX Amsterdam, the Netherlands.

18 ⁴Sanquin Blood Supply Foundation and Amsterdam University Medical Centre, Amsterdam, the
19 Netherlands.

20 ⁵Department of Infectious Diseases, Public Health Service region Utrecht, Utrecht, the Netherlands.

21 ⁶Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the
22 Netherlands.

23 ⁷Sanquin Blood Bank, Unit Transfusion Medicine, Leiden, the Netherlands.

24 ⁸Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine,
25 Utrecht University, 3584 CL Utrecht, the Netherlands.

26 ⁹Department of Virology, Sanquin Diagnostic Services, Amsterdam, The Netherlands.

27

28

29 **Corresponding author**

30 Theo Rispens; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and
31 Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The
32 Netherlands; T.Rispens@sanquin.nl.

33

34

35 **Keywords**

36 Longitudinal; ACE2 competition ELISA; neutralization; antibodies; COVID-19

37

38 Abstract

39 The novel SARS-CoV-2 virus emerged in late 2019 and has caused a global health and economic crisis. The
40 characterization of the human antibody response to SARS-CoV-2 infection is vital for serosurveillance
41 purposes as well for treatment options such as transfusion with convalescent plasma or immunoglobulin
42 products derived from convalescent plasma. In this study, we measured antibody responses in 844
43 longitudinal samples from 151 RT-PCR positive SARS-CoV-2 convalescent adults during the first 34 weeks
44 after onset of symptoms. All donors were seropositive at the first sampling moment and only one donor
45 seroreverted during follow-up analysis. Anti-RBD IgG and anti-nucleocapsid IgG levels slowly declined
46 with median half-life's of 62 and 59 days during 2-5 months after symptom onset, respectively. The rate
47 of decline of antibody levels diminished during extended follow-up. In addition, the magnitude of the IgG
48 response correlated with neutralization capacity measured in a classic plaque reduction assay as well in
49 our in-house developed competition assay. The result of this study gives valuable insight into the
50 longitudinal response of antibodies to SARS-CoV-2.

51

52 Introduction

53 The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative
54 agent of the on-going coronavirus disease (COVID-19) pandemic emerged in Wuhan (China) in December
55 2019. SARS-CoV-2 is classified under the *Betacoronavirus* 2B and is closely related to SARS-CoV (>80%
56 genomic similarity) and MERS-CoV (50% genomic similarity), which are known of previous outbreaks [1,
57 2]. COVID-19 is a disease that is associated with a wide spectrum of disease severity, ranging from
58 asymptomatic to acute respiratory distress syndrome and is already responsible for more than 1 million
59 deaths worldwide [3].

60 Besides vaccination, prevention of infection with SARS-CoV-2 might be achieved by transfusion with
61 COVID-19 convalescent plasma (CCP), plasma collected from individuals after recovery from COVID-19,
62 or immunoglobulin products derived from CCP [4-6]. This therapy would be especially relevant for
63 immunocompromised individuals. Although it has been shown that CCP therapy is safe [7] and it has been
64 approved by the FDA for treatment, the clinical effect especially in severely ill patients seems to be limited
65 [8]. The most potent CCP units are in theory those containing the highest amounts of neutralizing
66 antibodies against SARS-CoV-2. To select convalescent plasma donors with high neutralizing antibody
67 titers it is important to understand the dynamics of antibodies against SARS-CoV-2 in the period after
68 recovery from SARS-CoV-2.

69 Virtually all PCR-confirmed patients develop IgM, IgA and IgG antibodies against the virally encoded
70 surface glycoproteins spike (S) and nucleocapsid protein (NP) [9-11]. The S protein mediates binding of
71 the virus particle to angiotensin converting enzyme-2 (ACE2) on target cells through its receptor binding
72 domain (RBD) [12, 13], enabling merging of viral and target cell membrane. While a large fraction of anti-
73 S antibodies are directed against RBD, of which many are neutralizing [14, 15], anti-S antibodies binding
74 outside of the RBD may also contribute to neutralization [14, 15]. In addition, antibody levels seem to
75 vary depending on the infection duration and severity of disease, and anti-S and anti-NP antibodies
76 correlate well [16].

77 Seroprevalence studies have demonstrated that antibodies to SARS-CoV-2 can be detected up to at least
78 3-8 months after disease recovery [17-20]. However, seroprevalence depends on the characteristics of
79 the study population, on the detection methods used and do not report on the quantitative aspects of
80 the antibody response. Many short-term studies consistently show a seroconversion of IgG, IgA and IgM
81 antibodies against the viral proteins S and NP within 1-3 weeks after symptom onset, depending on
82 disease severity [9-11, 21]. Less information is available about the long-term course of antibody titers.
83 Several studies investigated the longitudinal antibody response and found that 1 month after onset of
84 symptoms antibody levels reach a plateau followed by rapidly declining IgM and IgA titers, whereas IgG
85 titers seems to remain high up to 6 months [18, 19, 22-26]. A recent study by Dan *et al.*, in which patients
86 were followed up to 8 months, consistently showed only a modest decline in anti-S IgG titers as well as
87 neutralizing antibody titers [20]. Limitations of these studies include a sometimes limited cohort size, and
88 in particular the number of longitudinal data points available for each subject, which restricts the
89 possibilities to analyze trends in antibody levels over time.

90 Here we collected samples from 151 RT-PCR positive SARS-CoV-2 recovered adults donating convalescent
91 plasma over a study period of up to 34 weeks. The median number of samples per donor was 5 (IQR 4-7;
92 range 2-18), which allowed a more detailed analysis of individual trends over time.

93 **Materials and Methods**

94 *Samples and donors*

95 Plasma samples were obtained from RT-PCR positive SARS-CoV-2 recovered adult individuals (n=151)
96 donating convalescent plasma at Sanquin Blood Bank (Amsterdam, the Netherlands) who enrolled the CP
97 program of Sanquin between March 30, 2020 and September 6, 2020. Donors were included if tested
98 positive in a SARS-CoV-2 PCR, which during this period was only provided to individuals displaying COVID-
99 19 related symptoms, and were symptom-free for at least two weeks. Details are provided in Table 1.
100 Inclusion was contingent upon the availability of at least two samples with 30 days in between and
101 samples were collected between March 30 and August 14, 2020 (period 1), yielding 694 samples.
102 Additional samples were collected based on availability for 55 donors up to November 11, 2020 (period
103 2), yielding another 150 samples. During this period many donors dropped out due to insufficient titers.
104 Some donors with low titers continued as regular plasma donor. The median number of samples per
105 donor was 5 (IQR 4-7; range 2-18).

106 Data and samples were collected only from voluntary, non-remunerated, adult donors as described
107 previously [27], and who provided written informed consent as part of routine donor selection and blood
108 collection procedures, that were approved by the Ethics Advisory Council of Sanquin Blood Supply
109 Foundation. This study has been conducted in accordance with the ethical principles set out in the
110 declaration of Helsinki and all participants provided written informed consent.

111 *Total and isotype-specific antibody ELISA*

112 Total antibody, IgM and IgA to RBD was measured as described previously [9]. IgG to RBD and NP were
113 measured essentially as described before [9], but with several modifications. RBD and NP proteins were
114 produced as described in Vogelzang *et al.*, [9]. IgG1 and IgG3 subclasses were detected by adding 0.5
115 µg/mL HRP-conjugated monoclonal mouse antihuman IgG1 (MH161.1, Sanquin) or 1.0 µg/mL antihuman
116 IgG3 (MH163.1, Sanquin) diluted in PBS supplemented with 0.02% polysorbate-20 and 0.3% gelatin) (PTG)
117 for 30 minutes. Samples were tested 1:1200 diluted for IgG and IgG1 to RBD, and 1:100 diluted for IgG3
118 to RBD. A cut-off was based on the 98 percentile of signals of 240 pre-outbreak plasma samples. Signals
119 were quantified using a serially diluted calibrator consisting of pooled convalescent plasma that was
120 included on each plate. This calibrator was arbitrarily assigned a value of 100 AU/mL. For anti-RBD IgG1
121 and IgG3, the calibrator consisted of recombinantly expressed IgG1 and IgG3 monoclonal antibody. Both
122 antibodies had the same variable regions (clone 1-18), but were engineered with different heavy chains
123 [15, 28]. Results were expressed as arbitrary units per mL (AU/mL) and represent a semi-quantitative
124 measure of the concentrations of IgG antibodies.

125

126 *Competition ELISA*

127 Neutralizing capacity of SARS-CoV-2 antibodies was assessed using a competition assay. Serum samples
128 were incubated 125-fold diluted for 60 minutes with 5 ng/mL biotinylated RBD in PTG. Next, 100 μ L
129 aliquots were transferred to MaxiSORP microtiter plates (ThermoFisherScientific, USA) coated with 300
130 ng/mL ACE2 and incubated for 60 minutes. The ACE2 was produced in HEK cells with a HAVT20 leader
131 peptide, 10xhis-tag and a BirA-tag as described by Dekkers *et al.*, [28]. After washing 5 times with PBS
132 supplemented with 0.02% polysorbate-20 (PBS-T), plates were incubated for 30 minutes with
133 streptavidin-poly-HRP (M2032, Sanquin). Plates were washed five times with PBS-T, and 100 μ L of TMB
134 substrate (100 μ g/mL) and 0.003% (v/v) hydrogen peroxide (Merck, Germany) in 0.11 M sodium acetate
135 buffer (pH 5.5) was added to each well. A total of 100 μ L of 0.2 M H₂SO₄ (Merck, Germany) was added to
136 stop the reaction. Absorbance was measured at 450 nm and 540 nm. The difference was used to evaluate
137 RBD binding. As such, results were corrected for background signals (absence of RBD) and expressed as
138 percentage binding relative to the uninhibited condition (% non-inhibited signal).

139 *Neutralization assay*

140 Sera were tested by a SARS-CoV-2-specific virus neutralization test (VNT) based on a protocol described
141 previously with some modifications [29]. In brief, replicate serial dilutions of heat-inactivated samples (30
142 minutes at 56°C) were incubated with 100-fold tissue culture 50% infectious dose of SARS-CoV-2 for 1
143 hour at 35°C. African green monkey (Vero-E6) cells were added in a concentration of 2×10^4 cells per well
144 and incubated for 3 days at 35°C in an incubator with 5% carbon dioxide. The 50% virus neutralization
145 titer (VNT50), defined as the highest serum dilution that protected more than 50% of cells from
146 cytopathological (lysed cells) effect, was taken as the neutralization titer. Samples with titers ≥ 10 were
147 defined as SARS-CoV-2 seropositive.

148 *Data processing and analysis*

149 Initial evaluation of IgG levels resulted in identification of 20 samples for which we observed either a >4-
150 fold drop in level/wk or 4-fold difference/2 wk with consecutive follow-up before and after. These were
151 excluded from all further analyses.

152 For the remaining 676 samples collected between March 30 and August 14, the longitudinal changes in
153 IgG antibody levels were analyzed by linear mixed effects modeling in R (v3.6.0) using the LmerTest
154 package (v3.1.2). We assumed first-order decay in concentrations, and therefore a linear trend in the log-
155 transformed concentrations with time. Time was used as fixed variable, with random intercept for subject
156 and random slope for time to account for individual clearance rates.

157 Statistical analysis were carried out using Graphpad Prism 7. Subgroup analysis on individual baseline
158 parameters (Table 1) was performed using either a Mann-Whitney test or Z test for proportions.
159 Correlations were evaluated as Spearman rank-order coefficient.

160

161

162 Results

163 A total of 151 adult CCP donors were selected who were tested RT-PCR positive (nasopharyngeal swab)
164 for SARS-CoV-2 (baseline information can be found in Table 1). On average, the first donation was
165 collected 59 days after onset of COVID-19 symptoms. Additional plasma samples per donor were
166 sequentially collected for up to 34 weeks after onset of symptoms, resulting in 844 plasma samples in
167 total. Of these, 20 samples were excluded as outliers (details see M&M), resulting in 676 samples for
168 **period 1** (up to 22 weeks after symptom onset; last sample median 110 days after symptom onset) and
169 another 148 samples for **period 2** (extending to 34 weeks after symptom onset). During period 2, many
170 donors were no longer donating due to insufficient titers, and this extended range is thus only available
171 for a biased selection of plasma donors (n=55). Initial analysis of the antibody response to SARS-CoV-2
172 was therefore focused on period 1.

173 *Seroprevalence of antibodies against RBD*

174 To study seroprevalence to SARS-CoV-2 we used our recently described sensitive total antibody bridging
175 assay (so called RBD-Ab) to RBD [9]. All donors were positive for SARS-CoV-2 antibodies as assessed with
176 the RBD-Ab assay, except for two samples, which belong to one donor that seroreverted at week 13 after
177 tested positive at week 10 (Figure 1A). In addition, using isotype-specific assays [9] we determined
178 seroprevalence of IgA, IgG and IgM to RBD. All samples collected before week 5 were seropositive for IgG
179 against RBD (Figure 1A). As time progressed only a small fraction of samples fell below the detection limit
180 for IgG, indicative that IgG levels remain in circulation for substantial periods after recovery, consistent
181 with other studies [18, 19]. In contrast, the amount of samples that were seropositive in the IgA and IgM
182 isotype specific assay were 75% and 68.8% before week 5, respectively, and gradually declined during the
183 study period, in line with previous studies [18, 19].

184 *Levels of IgG antibody responses against RBD and NP*

185 To obtain better insight into the antibody response we quantitatively analyzed the SARS-CoV-2 IgG
186 antibodies against NP and RBD in all 151 adult donors. For (relative) quantification, we made use of
187 pooled plasma of CCP donors as calibrator. Antibody concentrations varied >100-fold between individuals
188 for both anti-RBD and anti-NP, in line with a recent study by Dan *et al.*, [20] and were significantly
189 correlated (Figure 1B). In addition, consistent with other studies high concentrations were significantly
190 associated with hospitalization (Table 1) [30, 31]. Levels were also significantly higher in males than
191 females. However, this is largely due to more men being hospitalized (22 vs 0%); and no significant
192 difference was observed between non-hospitalized males and females (22 vs 17 AU/ml, and 22 vs 16
193 AU/ml, for anti-RBD and anti-NP, resp.; $p = 0.28$, and 0.14).

194 We also measured the IgG1 and IgG3 subclass responses to RBD at first donation in subclass-specific ELISA
195 assays. To properly allow quantitative comparison, we recombinantly expressed IgG1 and IgG3
196 monoclonal antibodies [15], which were used as a calibrator. We observed that IgG anti-RBD consisted
197 mainly of IgG1, median for IgG3 is 2.5% (IQR 1.5 – 5.1%; Figure S2A). Since higher subclass ratios were

198 reported for antibodies against the S2 vs S1 domain of the S protein [32, 33], we also tested IgG1 and
199 IgG3 in a subset of samples against the full S protein, but we obtained very similar results (Figure S2B).
200 Since titrations of the recombinant antibodies were parallel to the plasma pool used as calibrator (Figure
201 S2D), this also enabled us to estimate the absolute concentration of RBD-reactive IgG antibodies. The
202 average concentration of anti-RBD IgG observed in CP donors of 24 AU/ml was found to reflect
203 approximately 2-3 $\mu\text{g}/\text{mL}$.

204 *Dynamic changes in IgG against SARS-CoV-2*

205 Next, we assessed the dynamics of the IgG antibody response over time. Within the time window of up
206 to 22 weeks, most individuals demonstrated a steady, and approximately log-linear decline in antibody
207 concentration (Figure 1C,D). Assuming a log-linear (i.e., first-order) decline in antibody concentrations,
208 we analyzed this trend using linear mixed effects modeling, and found a median half-life of 62 (IQR 48 –
209 87) and 59 (IQR 44 – 82) days for anti-RBD and anti-NP IgG levels, respectively (Figure 2A and 2B and Table
210 1). There is a very weak correlation between estimated half-life for anti-RBD IgG and anti-NP IgG levels,
211 as shown in Figure 2C (Spearman $r = 0.23$, $p = 0.0037$). However, the subset of individuals demonstrating
212 the most rapid decline do so for both types of antibodies. There is a significant but weak negative
213 correlation between half-life and absolute levels (Figure S1), indicating a more rapid decline in individuals
214 with the highest antibody levels.

215 Although IgG3 has a shorter half life than IgG1, we did not observe an association between IgG clearance
216 rate and IgG1 and IgG3 levels in the first sample (Figure S2C), also not for those samples with a relatively
217 high percentage of IgG3 antibodies. In fact, the half-lives of the IgG anti-RBD and anti-NP levels exceed
218 the intrinsic half-life of both IgG3 antibodies (ca. 7 days) and IgG1 antibodies (ca. 21 days) [34], in line
219 with continued antibody production.

220 For a subset of 55 donors extended follow-up was available for up to 34 weeks (period 2). Of note, as
221 explained in the M&M, there is a selection bias in this group towards higher antibody levels for period 2.
222 Overall, the declining trends in antibody levels continued (Figure 3A,B). Interestingly, the rate of decline
223 appears to decrease at later time points, especially for donors with an initially high decline (Figure S3).
224 The effect is more pronounced for anti-RBD (Figure 3C) than anti-NP (Figure 3D).

225 *IgG levels correlate with viral neutralization*

226 To obtain insight into the neutralizing capacity of the antibody response in this population, we carried
227 out a competition ELISA in which binding of RBD to ACE2, the receptor on SARS-CoV-2 target cells, is
228 inhibited by blocking antibodies from plasma samples (Figure S4). We observed a high and significant
229 correlation between anti-RBD IgG levels and the amount of competition (Figure 4A), independent of the
230 timing of plasma collection (Figure 4B). On the other hand, correlation between anti-RBD IgM or IgA and
231 competition was very weak (Figure S5). This indicates that IgG probably plays an important role in
232 neutralizing SARS-CoV-2 virus particles, especially at the long term. Furthermore, we tested virus
233 neutralization of a subset of the plasma samples ($n = 147$) using the well-established classic plaque
234 reduction assay using live SARS-CoV-2 virus. We observed a good correlation between plaque reduction,
235 expressed as the titer that reduced plaque formation by 50% (VNT50), with anti-RBD IgG (Figure 4C) as

236 well with viral neutralization (Figure 4D) in the in-house competition assay. This data also indicates that
237 our ELISA-based competition assay could be used to evaluate the virus neutralizing capacity of anti-SARS-
238 CoV-2 antibodies in plasma samples.

239 Discussion

240 Here we describe the individual dynamics of the longitudinal antibody response in plasma samples from
241 CCP donors that were followed for up to 34 weeks post onset of COVID-19 disease symptoms. IgG levels
242 against RBD and NP decreased only gradually, albeit with substantial interindividual variation, and the
243 decrease appeared to slow down as time progressed. This information is relevant not only in the context
244 of the persistence of detectable antibody responses over time and the assessment of seroprevalence and
245 immunity in populations, but may also be used to improve the selection procedure of CCP donors for
246 therapies with convalescent plasma.

247 The median half-lives of 62 (48 – 87) and 59 (44 – 82) days for anti-RBD and anti-NP IgG, respectively, are
248 reasonably similar if slightly shorter to those found in Dan *et al.*, [20], that reported a half-life of 83 days
249 (62 – 127) for anti-RBD IgG and 67 days (49 – 105) for anti-NP IgG. The difference may be explained by
250 the fact that Dan *et al.* only used paired samples from individuals that donated 6 days and 8 months post
251 onset of symptoms. Our study included a median number of 5 samples per donor, which allowed a more
252 thorough analysis of individual rate profiles. The data suggests that the decline in antibody levels is not
253 uniform during this 8 months period, but continues at a slower pace at later time points. The reported
254 half-lives in this study reflect the period between ca. 2 and 5 months post symptom onset. Interestingly,
255 individuals showed a considerable, several-fold differences in IgG half-lives. A limitation is the substantial
256 uncertainty in the individual half-life estimates especially at the low end, since the available data will
257 sometimes only cover a fraction of a half-life.

258 Long-term maintenance of antibody production is provided by a pool of long-lived plasma cells and
259 memory B-cells that can last a lifetime [35]. Several time scales may be identified, of which the longest-
260 lasting can have half-lives in the order of many years, and thus beyond scope of the current study [36]. It
261 will be interesting to continue following the decline of anti-RBD IgG in time and investigate whether the
262 longevity of the antibody response is similar to other coronaviruses, such as SARS-CoV that can still be
263 detected in most individuals 3-years after recovery [37]. The antibody titer required for protection against
264 re-infection in humans is not yet known, and has to be evaluated also in the context of a recall response
265 upon re-infection. Recent studies provide evidence that upon infection, individuals develop SARS-CoV-2
266 specific memory B and memory T cells that can be detected for up to 240 days, with numbers of IgG
267 memory B cells increasing over time and plateauing after ca. 150 days [20, 38]. The relationship between
268 long-lasting antibody production and the T and B cell memory compartments requires more investigation.
269 We also quantitatively examined the IgG1 and IgG3 subclass response and found that in our study
270 population IgG1 appeared to be by far the dominant IgG subtype. This is in contrast to previous studies
271 that suggest an IgG subclass ratio skewed towards IgG3 during SARS-CoV-2 infection [33, 39]. A possible
272 explanation for this discrepancy is that in these studies the plasma samples were collected shortly after
273 COVID-19 disease recovery, while in our study samples were collected up to 22 weeks after onset of

274 disease symptoms. A strength of the current study is the use of matching IgG1 and IgG3 monoclonal anti-
275 S antibodies that allowed reliable quantification of the relative amounts of IgG1 and IgG3.
276 The dynamics of the SARS-CoV-2 antibodies play an important role in CCP donor recruitment in order to
277 select the most optimal timing of plasma collection, in which the level of IgG probably plays a crucial role.
278 Potent CCP units should in theory contain high amounts of neutralizing antibodies against SARS-CoV-2.
279 We observed a good correlation between anti-RBD IgG and both a classic plaque reduction viral
280 neutralization assay, consistent with previous studies [40, 41], as well as a straightforward competition
281 ELISA that indirectly assesses viral neutralization by measuring the ability of plasma containing anti-SARS-
282 CoV-2 antibodies to prevent interaction between RBD and ACE2. This suggests that a competition assay
283 may also reliably report on viral neutralization. Of note, a recent study by Gasser *et al.*, found that
284 depletion of IgM resulted in a substantial loss of virus neutralization of the corresponding plasma
285 samples, suggesting a role of IgM in virus neutralization [42]. However, IgM (and IgA) levels will drop
286 relatively fast after recovery. Indeed, many plasma donations did not contain detectable amounts of IgM
287 or IgA. Accordingly, we observed only a very weak correlation between viral neutralization in the
288 competition assay and IgM levels.
289 In line with other studies, higher IgG levels were found for patients that were hospitalized than those
290 with milder symptoms not requiring hospitalization, indicating that severely ill patients are more suitable
291 for CCP donation [21]. Nevertheless, there are potential caveats for these donors. First, a recent study by
292 Larsen *et al.*, showed that severely ill COVID-19 patients with acute respiratory distress syndrome may
293 display a so-called “afucosylated IgG anti-S response” [43, 44]. In addition, multiple studies reported the
294 presence of autoantibodies against a.o. type I IFN- α 2 and IFN- ω in patients with severe COVID-19
295 pneumonia that also show high IgG titers [45-49]. These parameters might negatively impact the outcome
296 of therapies with convalescent plasma, and suggest that it may be safer to rely on convalescent plasmas
297 from patients with mild symptoms, despite the fact that those tend to have lower antibody-response. In
298 conclusion, this study provides insight into the individual dynamics of antibody levels to SARS-CoV-2
299 during up to 34 weeks after symptom onset. Substantial (several-fold) variation in individual half-lives was
300 observed, with median half-lives of around 60 days for both anti-RBD and anti-NP IgG, and a tendency
301 towards slower rates of decline of antibody levels as time progressed.

302 Acknowledgements

303 We would like to thank all the donors who have kindly donated plasma.

304 Conflict of interest

305 Authors declare no conflict of interest.

306 List of abbreviations

- 307 • RBD: receptor binding domain
- 308 • NP: nucleocapsid protein
- 309 • S: spike

- 310 • SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- 311 • ACE2: angiotension converting enzyme-2
- 312 • VNT50: virus neutralization titer 50%
- 313 • Ab: antibody
- 314 • PTG: PBS supplemented with 0.02% polysorbate-20 and 0.3% gelatin

315 Funding

316 This study was supported by the European Commission (SUPPORT-E, grant number 101015756) and by
317 ZonMW (Protective Immunity, grant number 10430 01 201 0012).

318

319 References

- 320 1. Lu, R., *et al.*, *Genomic characterisation and epidemiology of 2019 novel coronavirus: implications*
321 *for virus origins and receptor binding*. The Lancet, 2020. **395**(10224): p. 565-574.
- 322 2. Ren, L.L., *et al.*, *Identification of a novel coronavirus causing severe pneumonia in human: a*
323 *descriptive study*. Chin Med J (Engl), 2020. **133**(9): p. 1015-1024.
- 324 3. Available from: <https://covidstatistics.org/>.
- 325 4. Casadevall, A., M.J. Joyner, and L.-A. Pirofski, *A Randomized Trial of Convalescent Plasma for*
326 *COVID-19—Potentially Hopeful Signals*. JAMA, 2020.
- 327 5. Chai, K.L., *et al.*, *Convalescent plasma or hyperimmune immunoglobulin for people with COVID-*
328 *19: a living systematic review*. Cochrane Database Syst Rev, 2020. **10**: p. CD013600.
- 329 6. Joyner, M.J., *et al.*, *Effect of Convalescent Plasma on Mortality among Hospitalized Patients with*
330 *COVID-19: Initial Three-Month Experience*. medRxiv, 2020.
- 331 7. Joyner, M.J., *et al.*, *Early safety indicators of COVID-19 convalescent plasma in 5000 patients*. J
332 Clin Invest, 2020. **130**(9): p. 4791-4797.
- 333 8. Libster, R., *et al.*, *Prevention of severe COVID-19 in the elderly by early high-titer plasma*. Preprint,
334 2020.
- 335 9. Vogelzang, E.H., *et al.*, *Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of*
336 *Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19*. J
337 Immunol, 2020.
- 338 10. Post, N., *et al.*, *Antibody response to SARS-CoV-2 infection in humans: a systematic review*.
339 Preprint, 2020.
- 340 11. Hueston, L., *et al.*, *The Antibody Response to SARS-CoV-2 Infection*. Open Forum Infect Dis, 2020.
341 **7**(9): p. ofaa387.
- 342 12. Tai, W., *et al.*, *Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus:*
343 *implication for development of RBD protein as a viral attachment inhibitor and vaccine*. Cell Mol
344 Immunol, 2020. **17**(6): p. 613-620.
- 345 13. Lan, J., *et al.*, *Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2*
346 *receptor*. Nature, 2020. **581**(7807): p. 215-220.
- 347 14. Premkumar, L., *et al.*, *The receptor binding domain of the viral spike protein is an*
348 *immunodominant and highly specific target of antibodies in SARS-CoV-2 patients*. Science
349 Immunology, 2020.
- 350 15. Philip J. M. Brouwer¹, *et al.*, *Potent neutralizing antibodies from COVID-19 patients define*
351 *multiple targets of vulnerability*. Science, 2020. **369**.
- 352 16. Li, K., *et al.*, *Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and*
353 *recovery from COVID-19*. Nat Commun, 2020. **11**(1): p. 6044.
- 354 17. Wang, K., *et al.*, *Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2*
355 *infection*. Clin Infect Dis, 2020.
- 356 18. Seow, J., *et al.*, *Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection*.
357 medRxiv, 2020.
- 358 19. Wu, J., *et al.*, *SARS-CoV-2 infection induces sustained humoral immune responses in convalescent*
359 *patients following symptomatic COVID-19*. medRxiv, 2020.
- 360 20. Dan, J.M., *et al.*, *Immunological memory to SARS-CoV-2 assessed for greater than six months after*
361 *infection*. Preprint, 2020.
- 362 21. Choe, P.G., *et al.*, *Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic*
363 *Patients*. PLoS One, 2020. **15**(4): p. e0231924.
- 364 22. Iyer, A.S., *et al.*, *Dynamics and significance of the antibody response to SARS-CoV-2 infection*.
365 medRxiv, 2020.
- 366 23. Perreault, J., *et al.*, *Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma*
367 *samples within 4 months after symptom onset*. Blood, 2020. **136**.
- 368 24. Padoan, A., *et al.*, *IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-*
369 *19: A longitudinal study*. Clin Chim Acta, 2020. **507**: p. 164-166.

- 370 25. Lucas, C., *et al.*, *Longitudinal analyses reveal immunological misfiring in severe COVID-19*. Nature,
371 2020. **584**(7821): p. 463-469.
- 372 26. Crawford, K.H.D., *et al.*, *Dynamics of neutralizing antibody titers in the months after SARS-CoV-2*
373 *infection*. Preprint, 2020.
- 374 27. van den Hurk, K., *et al.*, *Low awareness of past SARS-CoV-2 infection in healthy adults*. medRxiv,
375 2020.
- 376 28. Dekkers, G., *et al.*, *Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum*
377 *of Fc-Receptor- and Complement-Mediated-Effector Activities*. Front Immunol, 2017. **8**: p. 877.
- 378 29. Algaissi, A. and A.M. Hashem, *Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live*
379 *Virus Microneutralization Assay*. Methods Mol Biol, 2020. **2099**: p. 107-116.
- 380 30. Long, Q.X., *et al.*, *Antibody responses to SARS-CoV-2 in patients with COVID-19*. Nat Med, 2020.
381 **26**(6): p. 845-848.
- 382 31. Chen, W., *et al.*, *SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19*
383 *pneumonia*. Biomedicine & Pharmacotherapy, 2020. **130**: p. 110629.
- 384 32. Lee, C.Y., *et al.*, *Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance*
385 *and Control*. Front Immunol, 2020. **11**: p. 879.
- 386 33. Yates, J.L., *et al.*, *Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated*
387 *with COVID-19 Disease Severity*. medRxiv, 2020.
- 388 34. Stapleton, N.M., *et al.*, *Competition for FcRn-mediated transport gives rise to short half-life of*
389 *human IgG3 and offers therapeutic potential*. Nat Commun, 2011. **2**: p. 599.
- 390 35. Khodadadi, L., *et al.*, *The Maintenance of Memory Plasma Cells*. Front Immunol, 2019. **10**: p. 721.
- 391 36. Andraud, M., *et al.*, *Living on three time scales: the dynamics of plasma cell and antibody*
392 *populations illustrated for hepatitis a virus*. PLoS Comput Biol, 2012. **8**(3): p. e1002418.
- 393 37. Cao, W.-C., *et al.*, *Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery*. Th
394 e new engl and journal o f medicine, 2007.
- 395 38. Rodda, L.B., *et al.*, *Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19*.
396 Cell, 2020.
- 397 39. Ni, L., *et al.*, *Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19*
398 *Convalescent Individuals*. Immunity, 2020. **52**(6): p. 971-977 e3.
- 399 40. Peterhoff, D., *et al.*, *A highly specific and sensitive serological assay detects SARS-CoV-2 antibody*
400 *levels in COVID-19 patients that correlate with neutralization*. Infection, 2020.
- 401 41. Salazar, E., *et al.*, *Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-*
402 *binding domain IgG correlate with virus neutralization*. J Clin Invest, 2020. **130**(12): p. 6728-6738.
- 403 42. Gasser, R., *et al.*, *Major role of IgM in the neutralizing activity of convalescent plasma against*
404 *SARS-CoV-2*. 2020.
- 405 43. Larsen, M.D., *et al.*, *Afucosylated immunoglobulin G responses are a hallmark of enveloped virus*
406 *infections and show an exacerbated phenotype in COVID-19*. Preprint 2020.
- 407 44. Chakraborty, S., *et al.*, *Proinflammatory IgG Fc structures in patients with severe COVID-19*. Nat
408 Immunol, 2020.
- 409 45. Bastard, P., *et al.*, *Autoantibodies against type I IFNs in patients with life-threatening COVID-19*.
410 Science, 2020. **370**(6515).
- 411 46. Casciola-Rosen, L., *et al.*, *IgM autoantibodies recognizing ACE2 are associated with severe COVID-*
412 *19*. medRxiv, 2020.
- 413 47. Rauch, A., *et al.*, *Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated*
414 *With Organ Failure in Severe COVID-19*. Circulation, 2020. **142**(19): p. 1881-1884.
- 415 48. Woodruff, M.C., *et al.*, *Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection*.
416 medRxiv, 2020.
- 417 49. Zuo, Y., *et al.*, *Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19*.
418 2020. medRxiv.

419

420 **Table 1.** Baseline table for the convalescent plasma donors used in this study.


	Tot (n = 151)	Male (n = 105)	Female (n = 46)	<i>p</i>	Non-Hosp. (n = 128)	Hosp. (n = 23)	<i>p</i>
age (yr)	45 (35-55) ^{a)}	48 (36-55)	42 (29-51)	0.058	42 (31-53)	54 (48-58)	<0.001
M/F (%)	70				64	100	<0.001
Non-hosp./hosp. (%)	85	78	100	<0.001			
first donation (days after symptom onset)	59 (47-74)	59 (48-74)	54 (38-80)	0.61	54 (45-74)	63 (52-76)	0.13
IgG-RBD (AU/mL) ^{b)}	24 (9-70)	30 (10-89)	17 (9-28)	0.009	18 (8-39)	113 (70-223)	<0.001
IgG-NP (AU/mL) ^{b)}	28 (8-92)	35 (10-105)	16 (6-56)	0.012	19 (7-66)	117 (45-300)	<0.001
IgM-RBD (%) ^{b)}	49	55	35	0.024	45	70	0.027
IgA-RBD (%) ^{b)}	65	70	55	0.075	60	91	0.004
half-life RBD-IgG (days) ^{c)}	62 (48-87)	59 (47-84)	69 (53-99)	0.027	64 (49-93)	54 (47-68)	0.053
half-life NP-IgG (days) ^{c)}	59 (44-82)	58 (43-78)	67 (50-108)	0.023	60 (45-84)	54 (42-64)	0.12

a) numbers between parentheses indicate interquartile range

b) value at first donation


c) obtained from regression analysis

421



422
 423 **Figure 1. Antibodies against SARS-CoV-2 in CCP donors during up to 22 weeks of follow-up (period 1)**
 424 (A) Seropositivity was assessed by isotype-specific (IgM, IgA and IgG) assays and the total antibody assay
 425 RBD-Ab. Results were stratified per week (wk) post onset symptoms; samples covering < 5 and > 15 weeks
 426 were combined. B) Correlation between anti-RBD and anti-NP IgG levels. Samples from the CCP donors
 427 were tested in the RBD and NP IgG isotype specific assay and their correlation was evaluated by Spearman
 428 ($r = 0.73$, $p < 0.001$). (C) Concentrations of IgG anti-RBD and (D) anti-NP plotted in days after onset of
 429 disease symptoms (676 samples from 151 donors). Left, middle and right panels contain samples that
 430 were stratified according to fitted half-lives of antibody levels (see Figure 2).

431



432


433 **Figure 2. Regression analysis of IgG levels**

434 For both (A) RBD-IgG and (B) NP-IgG data of period 1 was modeled using a mixed effects model (log-linear
435 in IgG; random intercept and slope, time as fixed variable). Slopes of IgG decay in time (see Figure 1) were
436 converted into half-lives. Dotted vertical lines indicate median half-lives. (C) The correlation between
437 estimated half-lives for anti-RBD IgG and anti-NP IgG levels was evaluated by Spearman ($r = 0.23$, $p =$
438 0.0037). In case of rising levels, t was arbitrarily assigned a value of 1000 in the above figures (indicated
439 by grey bar (A,B) and red dots (C), respectively).

440

441

442




443

444 **Figure 3. Dynamic changes in IgG antibodies against SARS-CoV-2 during extended follow-up up to 34**
 445 **weeks (period 2)**

446 Concentrations of (A) IgG anti-RBD and (B) anti-NP plotted in days after onset of disease symptoms (430
 447 samples from 55 donors). Left panels 28 donors with fastest decline during period 1, right panels slowest
 448 27 donors. (C,D) Same data but normalized per donor using fitted intercepts from regression analysis of
 449 period 1. Blue and grey lines indicate median, smallest, and largest fitted slopes from same analysis
 450 (excluding positive slopes, 2 for RBD and 1 for NP) within both groups. Red lines are running averages
 451 showing overall trend within both groups of donors.

452

453



454

455

Figure 4. Correlation between IgG levels and virus neutralization

456

Plasma samples were tested in the in-house developed competition ELISA (676 samples from 151 individual donors), and in the classic plaque reduction assay (147 samples from 129 individual donors).

457

The correlation between anti-RBD IgG and virus neutralization in the (A, B) competition assay and (C)

458

plaque reduction assay was assessed by Spearman ($r = 0.85$, $r = 0.75$, resp., $p < 0.001$). (D) A correlation

459

between the two viral neutralization assays was also observed (Spearman $r = 0.65$, $p < 0.001$).

460


461

462

463 Supplementary information

464

465




466

467 **Figure S1. Correlation plots.**

468 Plots for fitted intercepts and slopes for (A, B) RBD-IgG and (C,D) NP-IgG with respect to measured IgG
469 levels at first donation. Interaction between slope and intercept/baseline IgG level: $r = 0.22$, $p = 0.006$
470 (RBD) and $r = 0.34$, $p < 0.0001$ (NP).

471



472

473

Figure S2. Contribution of IgG1 and IgG3 subclasses to anti-RBD

474

IgG1 and IgG3 antibody subtypes were measured against (A) RBD and (B) S1 and displayed as ratio IgG3 compared to IgG1. For RBD, first available sample for each donor was measured, for S, a random selection


475

of 30 donors was selected. (C) IgG3/IgG1 ratio vs clearance rate. (D) Titrations of IgG1 and IgG3 versions of the monoclonal antibody 1-18, and the plasma pool (PP) that was used as calibrator in this study.

476

477


478



479

480 **Figure S3. Normalized individual trends in IgG antibody levels during extended follow-up up to 34**
481 **weeks (period 2)**
482 Concentrations of (A) IgG anti-RBD and (B) anti-NP, normalized per donor using fitted intercepts from
483 regression analysis (Figure 2), plotted in days after onset of disease symptoms (430 samples from 55
484 donors). Left panels 28 donors with fastest decline during first 20 weeks, right panels slowest 27 donors.

485




486

487

488 **Figure S4. Overview of the competition assay.**

489 (A) schematic representation of the assay format. Biotinylated RBD will bind to immobilized ACE2 only to
490 the extent that neutralizing antibodies from serum do not inhibit this interaction. (B) dose-response
491 curves for several sera containing antibodies to Sars-CoV-2.

492



493

494 **Figure S5. Correlations of IgM and IgA anti-RBD with IgG anti-RBD and ACE2-RBD competition.**

495 Correlation between IgM (A) and IgA (B) with IgG anti-RBD in 676 samples of 151 donors collected up to
496 week 20 after symptom onset. Spearman $r = 0.41$ ($p < 0.0001$), and 0.23 ($p < 0.001$), resp. Correlation
497 between competition ELISA and IgM (C) and IgA (D) in the same set of samples. Spearman $r = -0.26$ ($p <$
498 0.001), $r = 0.22$ ($p < 0.001$), resp.

499